Stockreport

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor ant [Read more]